Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

 
Investor Presentation
Recent News
Jun 3, 2024

75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median tumor shrinkage of 47% by volume change after 6 months

May 31, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 30, 2024, the...

May 29, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming...

All Releases

Events
Monday, June 10, 2024
8:00am - 9:00am EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Corinne (Jenkins) Johnson, Vice President, Equity Research, Biotechnology

Wednesday, June 5, 2024
9:00am EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

All Events

Stock Info
NASDAQIDYA

Stock Information

Investor Contact

Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
650-443-6214
investor@ideayabio.com

Subscribe to email alerts
* Required Fields
WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

Close Menu